Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 29;20:492. doi: 10.1186/s12967-022-03711-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Comparisons between high-risk group and low-risk group. A The oncoplots of two risk subgroups showing significant mutation rate difference in some commonly mutated genes in bladder cancer. B Tumor mutation burden in the low-risk group was higher than that in the high-risk group(p < 0.05). C Higher Immunophenoscore in low-risk group indicates that the patients in low-risk group might have stronger immunogenicity and might be more sensitive to immunotherapy. D All types of infiltrating immune cells in high-risk group were more abundant than those in the low-risk group as calculated using the TIMER algorithm. E Low-risk group showed higher stemness indices than high-risk group. F Correlation matrix showing the relationship between risk score and immune factors. G–I 21 m6A regulator expression pattern (G), 11 m6A-immune-related lncRNAs expression pattern (H), and CIBERSORT immune infiltration pattern (I)